Contrast Media Market by Type (Iodinated Contrast Media), Modality (X-Ray/CT, MRI, and Ultrasound), Application (Radiology), End User (Hospitals), Indication (Cancer), Route of Administration (Oral) & Region - Global Forecast to 2027
Updated on : May 19, 2023
The global contrast media market in terms of revenue was estimated to be worth $5.1 billion in 2022 and is poised to reach $6.1 billion by 2027, growing at a CAGR of 3.7% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The expansion of this market is primarily due to the growing number of diagnostic procedures and the increasing popularity of minimally invasive procedures.
To know about the assumptions considered for the study, Request for Free Sample Report
Contrast Media Market Dynamics
Driver: Growing prevalence of chronic diseases
Globally, there has been a significant increase in the number of people suffering from cancer. In various countries across the globe, people are adopting a sedentary lifestyle, which is characterized by a high-calorie diet (that is rich in fat, refined carbohydrates, and animal protein) and low physical activity. With such changes in lifestyle, the number of people suffering from cancer is expected to increase. Contrast media are used to enhance the visualization of body structures and organs during diagnostic imaging procedures. The rising prevalence of chronic diseases such as cancer and CVD will result in the increased demand for advanced diagnostic imaging procedures, which, in turn, will drive the market for contrast media.
Opportunity: Increasing research on contrast agents
Rising R&D into novel contrast agents as well as the development of newer applications of contrast agents provide immense opportunities for market players. Companies, research institutes, and universities across the globe are undertaking projects to develop novel contrast agents and expand their applications. In 2020, a biochemistry and pharmacology professor, Dr. Gang Han, received USD 25,000 seed funding from UMass Technology Development Fund for research on MRI contrast media or gadolinium-based agents with fewer adverse effects.
Restraint: Side-effects and allergic reactions associated with contrast agents
Contrast agents are generally considered safe to use in various diagnostic procedures, such as MRI and CT scans. However, certain side-effects and allergic reactions associated with their use may limit market growth to a certain extent. Their adverse reactions range from mild to severe; severe reactions are very uncommon, and serious allergic reactions to contrast materials are rare.
Challenge: Restriction and withdrawal of linear gadolinium-based contrast agent
The use of linear gadolinium-based contrast agents in medical procedures was speculated to leave deposits in brain tissues. Further research has provided evidence in this regard, with confirmation from the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC). Following this, PRAC suspended intravenous linear gadolinium contrast agents (gadodiamide, gadopentetic acid, and gadoversetamide). This has led to the withdrawal of various products such as Magnevist (gadopentetic acid) by Bayer, Optimark (gadoversetamide) by Guerbet, and Omniscan (gadodiamide) by GE Healthcare from the European market. Manufacturers are also required to carry out clinical trials to determine whether additional measures are required, such as restrictions of use in certain patient groups or withdrawal of market approval. Regulatory restrictions for these agents will hamper their market growth in the coming years.
The cardiovascular disorders segment is expected to witness the highest CAGR in the contrast media market during the forecast period.
Based on indication, the market has been segmented into cardiovascular disorders, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. Cardiovascular disorders accounted for the largest market share and highest growth rate. The large share of this segment can be attributed to the rising geriatric population and the increasing prevalence of CVD across the globe.
Japan is anticipated to account the largest share of APAC Contrast media Market
Based on the Apac region, the market is divided into China, Japan, India, and Rest of APAC. Japan is expected to account the largest share of Contrast media. The presence of a well-established healthcare sector, a large and growing geriatric population, and the high incidence of chronic diseases in the country are the major factors supporting the growth of the Contrast media in Japan.
North America dominates the global Contrast media Market
Based on the region, the market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America is expected to dominate the Contrast media. Growth in the North American market is mainly driven by the increasing demand for early diagnosis and rising volume of CT and MRI examinations, rising geriatric population and the subsequent increase in the prevalence of chronic conditions in the US, and government investments in the field of medical imaging.
To know about the assumptions considered for the study, download the pdf brochure
The prominent players operating in the contrast media market include GE Healthcare (US), Bracco Imaging SPA (Italy), Bayer AG (Germany), and Guerbet (France).
Contrast Media Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$5.1 billion |
|
Projected Revenue by 2027 |
$6.1 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 3.7% |
|
Market Driver |
Growing prevalence of chronic diseases |
|
Market Opportunity |
Increasing research on contrast agents |
This research report categorizes the contrast media market to forecast revenue and analyze trends in each of the following submarkets:
By Type
- Iodinated Contrast Media
- Gadolinium-based Contrast Media
- Microbubble Contrast Media
- Barium-based Contrast Media
By Modality
- X-ray/CT
- MRI
- Ultrasound
By Route of Administration
- Intravascular Route
- Oral Route
- Rectal Route
- Other Route of Administration
By Indication
- Cardiovascular Disorders
- Cancer
- Gastrointestinal Disorders
- Musculoskeletal Disorders
- Neurological Disorders
- Nephrological Disorders
By Application
By End User
- Hospital, Clinics, & Ambulatory Surgery Centers
- Diagnostic Imaging Centers
By Region
- North America
-
US
- Canada
-
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
-
Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments
- In 2020, GE Healthcare Pharma Limited acquired the ownership of Daiichi Sankyo’s four diagnostic agents in Japan.
- In 2020, Bracco Imaging SpA received approval from the US FDA for its product ProHance, which is an MRI contrast agent for use in neonates and pediatric patients under two years of age.
- In 2019, Bayer AG received approval for Gadavist, a gadolinium-based contrast agent used in cardiac MRI for the diagnosis of coronary artery disease.
- In 2019, Guerbet and InterSystems Corporation (US) entered into the partnership aimed to expand Guerbet’s contrast media injection management solution.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global contrast media market?
The global contrast media market boasts a total revenue value of $6.1 billion by 2027.
What is the estimated growth rate (CAGR) of the global contrast media market?
The global contrast media market has an estimated compound annual growth rate (CAGR) of 3.7% and a revenue size in the region of $5.1 billion in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 41)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
FIGURE 1 CONTRAST MEDIA/CONTRAST AGENTS MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 45)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.2 SECONDARY DATA
2.2.1 SECONDARY SOURCES
2.3 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.3.1 KEY DATA FROM PRIMARY SOURCES
2.3.2 KEY INDUSTRY INSIGHTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.4 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.4.1 GROWTH FORECAST
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.6 MARKET SHARE ANALYSIS
2.7 ASSUMPTIONS FOR THE STUDY
2.7.1 COVID-19 SPECIFIC ASSUMPTIONS
2.8 LIMITATIONS
2.9 RISK ASSESSMENT
2.10 GROWTH RATE ASSUMPTIONS
2.11 COVID-19 ECONOMIC ASSESSMENT
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY (Page No. - 60)
FIGURE 11 CONTRAST MEDIA MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 CONTRAST MEDIA MARKET, BY MODALITY, 2021 VS. 2026 (USD MILLION)
FIGURE 13 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD MILLION)
FIGURE 14 CONTRAST MEDIA MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 CONTRAST MEDIA MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 16 CONTRAST MEDIA MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 17 CONTRAST MEDIA MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 67)
4.1 CONTRAST MEDIA MARKET OVERVIEW
FIGURE 18 INCREASING INCIDENCE OF CHRONIC DISORDERS TO DRIVE MARKET GROWTH
4.2 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE (2021–2026)
FIGURE 19 MICROBUBBLE CONTRAST MEDIA SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
4.3 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE AND COUNTRY (2020)
FIGURE 20 THE US DOMINATED THE NORTH AMERICAN CONTRAST MEDIA/CONTRAST AGENTS MARKET IN 2020
4.4 CONTRAST MEDIA MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 INDIA AND CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 71)
5.1 INTRODUCTION
FIGURE 22 CONTRAST MEDIA/CONTRAST AGENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of chronic diseases
TABLE 1 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
5.2.1.2 Growing approvals of contrast agents
5.2.1.3 Rising volume of CT and MRI examinations performed
TABLE 2 NUMBER OF MRI EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2010 VS. 2018
TABLE 3 NUMBER OF CT EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2010 VS. 2018
5.2.1.4 Growing number of diagnostic centers and hospitals
5.2.1.5 Availability of reimbursement
5.2.2 RESTRAINTS
5.2.2.1 Side-effects and allergic reactions associated with contrast agents
TABLE 4 LIST OF SIDE-EFFECTS/REACTIONS TO CONTRAST MEDIA
5.2.3 OPPORTUNITIES
5.2.3.1 Generic contrast media
5.2.3.2 Increasing research on contrast agents
TABLE 5 INDICATIVE LIST OF RESEARCH STUDIES
5.2.4 CHALLENGES
5.2.4.1 Technological advancements in imaging solutions
5.2.4.2 Restriction and withdrawal of linear gadolinium-based contrast agents
5.2.4.3 Dearth of trained professionals
TABLE 6 METROPOLITAN AREAS IN THE US WITH HIGH EMPLOYMENT LEVELS AMONG RADIOLOGY TECHNOLOGISTS AND TECHNICIANS
5.3 RANGES/SCENARIOS
5.3.1 CONTRAST MEDIA/CONTRAST AGENTS MARKET FORECAST
FIGURE 23 PESSIMISTIC SCENARIO
FIGURE 24 OPTIMISTIC SCENARIO
FIGURE 25 REALISTIC SCENARIO
5.4 COVID-19 IMPACT ON THE CONTRAST MEDIA/CONTRAST AGENTS MARKET
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.5.1 REVENUE SHIFT & REVENUE POCKETS FOR CONTRAST MEDIA/CONTRAST AGENT MANUFACTURERS
5.5.2 REVENUE SHIFT FOR CONTRAST MEDIA/CONTRAST AGENTS MARKET
5.6 PRICING ANALYSIS
TABLE 7 PRICES OF CONTRAST MEDIA/CONTRAST AGENTS
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 26 DIRECT DISTRIBUTION: A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.8 VALUE CHAIN ANALYSIS
FIGURE 27 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE DEVELOPMENT PHASE
5.9 ECOSYSTEM ANALYSIS
5.9.1 ROLE IN THE ECOSYSTEM
TABLE 8 ROLE OF KEY PLAYERS IN THE ECOSYSTEM
FIGURE 28 KEY PLAYERS IN THE CONTRAST MEDIA/CONTRAST AGENTS ECOSYSTEM
5.10 TECHNOLOGY ANALYSIS
5.11 PATENT ANALYSIS
5.12 TRADE ANALYSIS
TABLE 9 IMPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS; DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2016-2020 (USD MILLION)
TABLE 10 EXPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS; DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2016-2020 (USD MILLION)
5.13 REGULATORY LANDSCAPE
TABLE 11 LIST OF REGULATORY AUTHORITIES IN THE PHARMACEUTICAL INDUSTRY
5.13.1 EU REGULATIONS
5.13.2 FDA REGULATIONS
5.13.3 JPMA REGULATIONS
5.14 PORTER’S FIVE FORCES ANALYSIS
TABLE 12 PORTER’S FIVE FORCES
5.14.1 INTENSITY OF COMPETITIVE RIVALRY
5.14.2 BARGAINING POWER OF SUPPLIERS
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 THREAT OF NEW ENTRANTS
6 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE (Page No. - 95)
6.1 INTRODUCTION
6.2 PRIMARY NOTES
TABLE 13 CONTRAST MEDIA MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 14 CONTRAST MEDIA MARKET, BY TYPE, 2020–2026 (USD MILLION)
6.3 IODINATED CONTRAST MEDIA
6.3.1 CONSUMPTION OF IODINATED CONTRAST MEDIA IS HIGH DUE TO THE HIGHER DOSAGE REQUIRED IN CT SCANS—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 15 IODINATED CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 16 IODINATED CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
6.4 GADOLINIUM-BASED CONTRAST MEDIA
6.4.1 SUSPICION REGARDING THE SAFETY PROFILE OF GADOLINIUM-BASED CONTRAST AGENTS TO CHALLENGE MARKET GROWTH TO A CERTAIN EXTENT
TABLE 17 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 18 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
6.5 MICROBUBBLE CONTRAST MEDIA
6.5.1 MICROBUBBLES ARE CONVENIENT, COMPLETELY RADIATION-FREE, AND VERSATILE, MAKING THEM EXTREMELY POPULAR WITH PHYSICIANS WORLDWIDE
TABLE 19 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 20 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
6.6 BARIUM-BASED CONTRAST MEDIA
6.6.1 BARIUM-BASED CONTRAST MEDIA CAN CAUSE ADVERSE EFFECTS IN PATIENTS LIKE PERFORATION OF THE PERITONEUM—THIS IS EXPECTED TO NEGATIVELY IMPACT THE MARKET
TABLE 21 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 22 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
7 CONTRAST MEDIA MARKET, BY MODALITY (Page No. - 104)
7.1 INTRODUCTION
7.2 PRIMARY NOTES
TABLE 23 CONTRAST MEDIA MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 24 CONTRAST MEDIA MARKET, BY MODALITY, 2020–2026 (USD MILLION)
7.3 X-RAY/CT
7.3.1 X-RAY/CT SEGMENT ACCOUNTS FOR THE LARGEST SHARE OF THE CONTRAST MEDIA/CONTRAST AGENTS MARKET
TABLE 25 NUMBER OF X-RAY AND CT SCANS IN ENGLAND
TABLE 26 INSTALLED BASE OF CT SCANNERS, BY REGION, 2017 VS. 2018
TABLE 27 CT PROCEDURAL VOLUMES, BY REGION, 2017 VS. 2018 (MILLION)
TABLE 28 X-RAY/CT CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 29 X-RAY/CT CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
7.4 MAGNETIC RESONANCE IMAGING
7.4.1 GROWING NUMBER OF MRI SCANNERS AND INCREASING MRI EXAMINATIONS ARE DRIVING MARKET GROWTH
TABLE 30 INSTALLED BASE OF MRI SYSTEMS, BY REGION, 2017 VS. 2018
TABLE 31 MRI PROCEDURAL VOLUMES, BY REGION, 2017 VS. 2018 (MILLION)
TABLE 32 NUMBER OF MRI PROCEDURES IN ENGLAND
TABLE 33 MRI CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 34 MRI CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
7.5 ULTRASOUND
7.5.1 ULTRASOUND SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
TABLE 35 NUMBER OF ULTRASOUND PROCEDURES IN ENGLAND
TABLE 36 ULTRASOUND CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 37 ULTRASOUND CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2020–2026 (USD MILLION)
8 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 113)
8.1 INTRODUCTION
TABLE 38 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 39 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
8.2 INTRAVASCULAR ROUTE
8.2.1 WIDESPREAD USE OF INTRAVASCULAR ROUTES OF ADMINISTRATION IN IMAGING MODALITIES TO DRIVE MARKET GROWTH
8.2.1.1 INTRAVENOUS (IV) ROUTE
8.2.1.2 INTRA-ARTERIAL (IA) ROUTE
TABLE 40 INTRAVASCULAR CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 41 INTRAVASCULAR CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
8.3 ORAL ROUTE
8.3.1 USE OF ORAL CONTRAST MEDIA CAN LEAD TO PERFORATIONS IN THE GIT, LEADING TO PERITONITIS—THIS MAY LIMIT MARKET GROWTH TO A CERTAIN EXTENT
TABLE 42 ORAL CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 43 ORAL CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
8.4 RECTAL ROUTE
8.4.1 MILD DISCOMFORT ASSOCIATED WITH RECTAL CONTRAST MEDIA TO LIMIT MARKET GROWTH
TABLE 44 RECTAL CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 45 RECTAL CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
8.5 OTHER ROUTES OF ADMINISTRATION
TABLE 46 OTHER CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 47 OTHER CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
9 CONTRAST MEDIA MARKET, BY INDICATION (Page No. - 121)
9.1 INTRODUCTION
9.2 PRIMARY NOTES
TABLE 48 CONTRAST MEDIA MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 49 CONTRAST MEDIA MARKET, BY INDICATION, 2020–2026 (USD MILLION)
9.3 CARDIOVASCULAR DISORDERS
9.3.1 CARDIOVASCULAR DISORDERS SEGMENT TO DOMINATE THE CONTRAST MEDIA/CONTRAST AGENTS MARKET
TABLE 50 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2017–2019 (USD MILLION)
TABLE 51 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2020–2026 (USD MILLION)
9.4 CANCER
9.4.1 ASIA PACIFIC MARKET TO REGISTER RELATIVELY HIGHER GROWTH OWING TO THE HIGH CANCER PREVALENCE IN THE REGION
TABLE 52 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 53 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CANCER, BY REGION, 2017–2019 (USD MILLION)
TABLE 54 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CANCER, BY REGION, 2020–2026 (USD MILLION)
9.5 GASTROINTESTINAL DISORDERS
9.5.1 RISING PREVALENCE OF GI DISORDERS TO SUPPORT MARKET GROWTH
TABLE 55 CONTRAST MEDIA MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2017–2019 (USD MILLION)
TABLE 56 CONTRAST MEDIA MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)
9.6 MUSCULOSKELETAL DISORDERS
9.6.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH
TABLE 57 CONTRAST MEDIA MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2017–2019 (USD MILLION)
TABLE 58 CONTRAST MEDIA MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)
9.7 NEUROLOGICAL DISORDERS
9.7.1 RISING PREVALENCE OF DEMENTIA TO DRIVE MARKET GROWTH
TABLE 59 CONTRAST MEDIA MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2017–2019 (USD MILLION)
TABLE 60 CONTRAST MEDIA MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)
9.8 NEPHROLOGICAL DISORDERS
9.8.1 RISING PREVALENCE OF ESRD IS DRIVING THE DEMAND FOR DIAGNOSTIC TOOLS FOR KIDNEY DISEASES
TABLE 61 CONTRAST MEDIA MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2017–2019 (USD MILLION)
TABLE 62 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)
10 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION (Page No. - 132)
10.1 INTRODUCTION
TABLE 63 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 64 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.2 RADIOLOGY
10.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE THE GROWTH OF THE RADIOLOGY APPLICATIONS SEGMENT
TABLE 65 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR RADIOLOGY, BY REGION, 2017–2019 (USD MILLION)
TABLE 66 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR RADIOLOGY, BY REGION, 2020–2026 (USD MILLION)
10.3 INTERVENTIONAL RADIOLOGY
10.3.1 INCREASING POPULARITY OF MINIMALLY INVASIVE PROCEDURES TO SUPPORT MARKET GROWTH
TABLE 67 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2017–2019 (USD MILLION)
TABLE 68 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2020–2026 (USD MILLION)
10.4 INTERVENTIONAL CARDIOLOGY
10.4.1 RISING INCIDENCE OF CARDIAC DISORDERS TO DRIVE THE DEMAND FOR INTERVENTIONAL CARDIOLOGY PROCEDURES
TABLE 69 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2017–2019 (USD MILLION)
TABLE 70 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2020–2026 (USD MILLION)
11 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER (Page No. - 139)
11.1 INTRODUCTION
TABLE 71 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 72 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
11.2 HOSPITAL, CLINICS, AND AMBULATORY SURGERY CENTERS
11.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES ACROSS HOSPITALS TO DRIVE MARKET GROWTH
TABLE 73 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2017–2019 (USD MILLION)
TABLE 74 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2020–2026 (USD MILLION)
11.3 DIAGNOSTIC IMAGING CENTERS
11.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO DRIVE MARKET GROWTH IN THE COMING YEARS
TABLE 75 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2017–2019 (USD MILLION)
TABLE 76 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2020–2026 (USD MILLION)
12 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION (Page No. - 144)
12.1 INTRODUCTION
TABLE 77 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION)
TABLE 78 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2020–2026 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET SNAPSHOT
TABLE 79 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
TABLE 80 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 81 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 82 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 83 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 84 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 85 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 86 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 87 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 88 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 89 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 90 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 91 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 92 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.2.1 US
12.2.1.1 The US dominates the North American contrast media/contrast agents market
TABLE 93 US: KEY MACROINDICATORS
TABLE 94 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 95 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 96 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 97 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 98 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 99 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 100 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 101 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 102 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 103 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 104 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 105 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.2.2 CANADA
12.2.2.1 Increasing investments in improving medical imaging—a major factor driving market growth in Canada
TABLE 106 CANADA: KEY MACROINDICATORS
TABLE 107 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 108 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 109 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 110 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 111 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 112 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 113 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 114 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 115 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 116 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 117 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 118 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.3 EUROPE
TABLE 119 TOTAL NUMBER OF MRI UNITS PER 1,000,000 INHABITANTS, 2017
TABLE 120 TOTAL NUMBER OF MRI EXAMS PER 1,000 INHABITANTS, 2017
TABLE 121 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
TABLE 122 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 123 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 124 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 125 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 126 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 127 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 128 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 129 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 130 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 131 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 132 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 133 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 134 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 Presence of a well-developed diagnostic imaging infrastructure is a major factor supporting market growth in Germany
TABLE 135 GERMANY: KEY MACROINDICATORS
TABLE 136 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 137 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 138 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 139 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 140 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 141 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 142 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 143 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 144 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 145 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 146 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 147 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.3.2 UK
12.3.2.1 Increasing investments in the field of diagnostic imaging to boost the market growth
TABLE 148 UK: KEY MACROINDICATORS
TABLE 149 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 150 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 151 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 152 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 153 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 154 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 155 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 156 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 157 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 158 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 159 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 160 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 Increasing prevalence of cancer will drive the market for contrast media in France
TABLE 161 FRANCE: KEY MACROINDICATORS
TABLE 162 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 163 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 164 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 165 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 166 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 167 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 168 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 169 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 170 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 171 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 172 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 173 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.3.4 SPAIN
12.3.4.1 Shortage of radiologists in the country to restrain the market growth
TABLE 174 SPAIN: KEY MACROINDICATORS
TABLE 175 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 176 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 177 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 178 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 179 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 180 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 181 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 182 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 183 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 184 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 185 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 186 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.3.5 ITALY
12.3.5.1 Rising geriatric population likely to drive the demand for diagnostic procedures in Italy
TABLE 187 ITALY: KEY MACROINDICATORS
TABLE 188 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 189 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 190 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 191 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 192 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 193 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 194 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 195 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 196 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 197 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 198 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 199 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.3.6 REST OF EUROPE
TABLE 200 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP)
TABLE 201 ROE: NUMBER OF UNITS AND NUMBER OF SCANS, BY COUNTRY, 2018
TABLE 202 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 203 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 204 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 205 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 206 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 207 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 208 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 209 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 210 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 211 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 212 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 213 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: CONTRAST MEDIA/CONTRAST AGENTS MARKET SNAPSHOT
TABLE 214 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
TABLE 215 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 216 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 217 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 218 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 219 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 220 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 221 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 222 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 223 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 224 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 225 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 226 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 227 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.4.1 JAPAN
12.4.1.1 Japan dominates the APAC contrast media/contrast agents market
TABLE 228 JAPAN: KEY MACROINDICATORS
TABLE 229 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 230 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 231 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 232 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 233 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 234 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 235 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 236 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 237 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 238 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 239 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 240 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.4.2 CHINA
12.4.2.1 High incidence of cancer and strokes will support the market for contrast media in China
TABLE 241 CHINA: KEY MACROINDICATORS
TABLE 242 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 243 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 244 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 245 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 246 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 247 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 248 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 249 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 250 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 251 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 252 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 253 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.4.3 INDIA
12.4.3.1 Growing investments in the Indian radiology market will propel market growth
TABLE 254 INDIA: KEY MACROINDICATORS
TABLE 255 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 256 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 257 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 258 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 259 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 260 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 261 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 262 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 263 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 264 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 265 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 266 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.4.4 REST OF ASIA PACIFIC
TABLE 267 NUMBER OF MRI AND CT UNITS PER MILLION POPULATION, PER COUNTRY, 2019
TABLE 268 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 269 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 270 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 271 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 272 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 273 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 274 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 275 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 276 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 277 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 278 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 279 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.5 LATIN AMERICA
12.5.1 INCREASING HEALTHCARE ACCESS IS EXPECTED TO DRIVE MARKET GROWTH
TABLE 280 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 281 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 282 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 283 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 284 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 285 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 286 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 287 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 288 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 289 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 290 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 291 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
12.6 MIDDLE EAST & AFRICA
12.6.1 POOR REIMBURSEMENT SYSTEMS EXPECTED TO RESTRAIN MARKET GROWTH
TABLE 292 ISRAEL: DIAGNOSTIC IMAGING DATA, 2019
TABLE 293 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
TABLE 294 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 295 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
TABLE 296 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 297 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
TABLE 298 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
TABLE 299 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
TABLE 300 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
TABLE 301 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
TABLE 302 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 303 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
TABLE 304 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
13 COMPETITIVE LANDSCAPE (Page No. - 234)
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 305 OVERVIEW OF STRATEGIES ADOPTED BY KEY CONTRAST MEDIA/CONTRAST AGENTS MARKET PLAYERS
13.3 MARKET SHARE ANALYSIS
FIGURE 31 CONTRAST MEDIA/CONTRAST AGENTS MARKET SHARE ANALYSIS, 2020
TABLE 306 CONTRAST MEDIA/CONTRAST AGENTS MARKET: DEGREE OF COMPETITION (2020)
13.4 COMPANY EVALUATION QUADRANT
13.4.1 STARS
13.4.2 EMERGING LEADERS
13.4.3 PERVASIVE PLAYERS
13.4.4 PARTICIPANTS
FIGURE 32 CONTRAST MEDIA/CONTRAST AGENTS MARKET: COMPANY EVALUATION QUADRANT, 2020
13.5 COMPANY EVALUATION QUADRANT: SME/START-UPS
13.5.1 PROGRESSIVE COMPANIES
13.5.2 STARTING BLOCKS
13.5.3 RESPONSIVE COMPANIES
13.5.4 DYNAMIC COMPANIES
FIGURE 33 CONTRAST MEDIA/CONTRAST AGENTS MARKET: COMPANY EVALUATION QUADRANT FOR SME & START-UPS, 2020
13.6 COMPETITIVE SCENARIO
FIGURE 34 MARKET EVALUATION MATRIX, 2018–2021
13.6.1 DEALS
TABLE 307 DEALS
13.6.2 PRODUCT LAUNCHES/APPROVALS
TABLE 308 PRODUCT LAUNCHES/APPROVALS
13.6.3 OTHER DEVELOPMENTS
TABLE 309 OTHER DEVELOPMENTS
13.7 COMPANY FOOTPRINT ANALYSIS
TABLE 310 COMPANY FOOTPRINT ANALYSIS
TABLE 311 COMPANY PRODUCT FOOTPRINT
TABLE 312 COMPANY MODALITY FOOTPRINT
TABLE 313 COMPANY GEOGRAPHICAL FOOTPRINT
14 COMPANY PROFILES (Page No. - 249)
14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 GE HEALTHCARE
TABLE 314 GE HEALTHCARE: BUSINESS OVERVIEW
FIGURE 35 GE HEALTHCARE: COMPANY SNAPSHOT (2020)
14.1.2 BRACCO IMAGING SPA
TABLE 315 BRACCO IMAGING SPA: BUSINESS OVERVIEW
14.1.3 BAYER AG
TABLE 316 BAYER AG: BUSINESS OVERVIEW
FIGURE 36 BAYER AG: COMPANY SNAPSHOT (2020)
14.1.4 GUERBET
TABLE 317 GUERBET: BUSINESS OVERVIEW
FIGURE 37 GUERBET: COMPANY SNAPSHOT (2020)
14.1.5 LANTHEUS MEDICAL IMAGING
TABLE 318 LANTHEUS MEDICAL IMAGING: BUSINESS OVERVIEW
FIGURE 38 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT (2020)
14.1.6 UNIJULES LIFE SCIENCES
TABLE 319 UNIJULES LIFE SCIENCES: BUSINESS OVERVIEW
14.1.7 J.B. CHEMICALS AND PHARMACEUTICALS
TABLE 320 J.B. CHEMICALS AND PHARMACEUTICALS: BUSINESS OVERVIEW
FIGURE 39 J.B. CHEMICALS AND PHARMACEUTICALS LTD: COMPANY SNAPSHOT (2020)
14.1.8 SANOCHEMIA PHARMAZEUTIKA
TABLE 321 SANOCHEMIA PHARMAZEUTIKA: BUSINESS OVERVIEW
14.1.9 TAEJOON PHARM
TABLE 322 TAEJOON PHARM: BUSINESS OVERVIEW
14.1.10 JODAS EXPOIM
TABLE 323 JODAS EXPOIM: BUSINESS OVERVIEW
14.1.11 NANO THERAPEUTICS
TABLE 324 NANO THERAPEUTICS: BUSINESS OVERVIEW
14.1.12 KIRAN X-RAY
TABLE 325 KIRAN X-RAY: BUSINESS OVERVIEW
14.1.13 IMAX DIAGNOSTIC IMAGING LIMITED
TABLE 326 IMAX DIAGNOSTIC IMAGING: BUSINESS OVERVIEW
14.1.14 YANGTZE RIVER PHARMACEUTICAL GROUP
TABLE 327 YZJ GROUP: BUSINESS OVERVIEW
14.1.15 LIVEALTH BIOPHARMA
TABLE 328 LIVEALTH BIOPHARMA: BUSINESS OVERVIEW
14.2 OTHER PLAYERS
14.2.1 TRIVITRON HEALTHCARE
14.2.2 NOVALEK PHARMACEUTICALS
14.2.3 UNISPIRE BIOPHARMA PRIVATE LIMITED
14.2.4 ARCO LIFESCIENCES
14.2.5 CONGRUENT PHARMACHEM PRIVATE LIMITED
14.2.6 STANEX DRUGS & CHEMICAL
14.2.7 BEIJING BEILU PHARMACEUTICAL
14.2.8 REGE IMAGING & CINE FILMS
14.2.9 K DIAM EXIM
14.2.10 ONKO ÝLAÇ SAN. VE TIC. A.Þ.
14.2.11 SUBHRA PHARMA
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX (Page No. - 291)
15.1 INSIGHTS FROM INDUSTRY EXPERTS
15.2 DISCUSSION GUIDE
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.4 AVAILABLE CUSTOMIZATIONS
15.5 RELATED REPORTS
15.6 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the contrast media/ contrast agents market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the contrast media/ contrast agents market. The secondary sources used for this study include European Society of Radiology (ESR), Society of Interventional Radiology (SIR), Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR), American College of Radiology (ACR), Organisation for Economic Co-operation and Development (OECD), International Society of Radiology (ISR), Radiological Society of North America (RSNA), Journal of Radiology, National Institutes of Health (NIH), International Life Sciences Institute (ILSI), National Kidney Foundation (NKF), American Association for Cancer Research (AACR), US Food and Drug Administration (US FDA), American Medical Association (AMA), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), Eurostat, SEC Filings, Annual Reports, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the contrast media/ contrast agents market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the contrast media/ contrast agents business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global contrast media market based on the type, procedure, application and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall contrast media/ contarst agents market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East & Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the contrast media/ contrast agents market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- An additional five company profiles
Generating Response ...
Growth opportunities and latent adjacency in Contrast Media Market
1) The contrast media/contrast agents market is segmented into barium-based contrast media, iodinated contrast media, gadolinium-based contrast media, and microbubble contrast media. In 2020, the iodinated contrast media segment accounted for the largest share of XX of the contrast media/contrast agents market. The large share of this segment can be attributed to the increasing demand for early disease diagnosis and image-guided procedures (resulting in a rising volume of CT and Xray procedures). 2) The barium-based contrast media market is expected to register low growth due to its limited use in various procedures and the associated adverse effects of these agents on organs. 3) Microbubble contrast agents are generally regarded as safe to use and are gaining popularity because of the large number of ongoing academic research activities exploring various attributes of microbubbles in off-label indications (in diagnosis as well as drug delivery). The growing number of approvals for microbubble contrast agents in major markets is also driving the growth of this market segment.
We need the list of vendors in Contrast Media Market. Please help
Can you please help us with study related to contrast media injectors market ?
We intend to import and sale to our customer non ionic contract media, X-Ray, Angiography, CT, MRI users, Please send us price list. M.Y.Zahid, [email protected]